The RNA-binding protein tristetraprolin (TTP) promotes rapid decay of mRNAs bearing 3' UTR AU-rich elements (ARE). In many cancer types, loss of TTP expression is observed allowing for stabilization of ARE-mRNAs and their pathologic overexpression. Here we demonstrate that histone deacetylase (HDAC) inhibitors (Trichostatin A, SAHA and sodium butyrate) promote TTP expression in colorectal cancer cells (HCA-7, HCT-116, Moser and SW480 cells) and cervix carcinoma cells (HeLa). We found that HDAC inhibitors-induced TTP expression, promote the decay of COX-2 mRNA, and inhibit cancer cell proliferation. HDAC inhibitors were found to promote TTP transcription through activation of the transcription factor Early Growth Response protein 1 (EGR1). Altogether, our findings indicate that loss of TTP in tumors occurs through silencing of EGR1 and suggests a therapeutic approach to rescue TTP expression in colorectal cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598787PMC
http://dx.doi.org/10.3390/biom5032035DOI Listing

Publication Analysis

Top Keywords

ttp expression
16
colorectal cancer
12
histone deacetylase
8
early growth
8
growth response
8
response protein
8
protein egr1
8
cancer cells
8
loss ttp
8
hdac inhibitors
8

Similar Publications

Background: Esophageal cancer (ESC) is an aggressive disease which often presents at an advanced stage. Despite trimodal therapy, 40-50% patients can develop metastatic disease by 18 months. Identification of patients at risk for metastatic spread is challenging with need for improved prognostication.

View Article and Find Full Text PDF

Background: TRK-inhibitors have demonstrated efficacy across several cancers with NTRK fusions. Their activity in cancers with NTRK overexpression remains unclear.

Methods: This trial enrolled patients with advanced cancers harboring NTRK fusions or extreme mRNA overexpression, defined as NTRK1/2/3 expression by RNA profiling >5 SDs for a given cancer type.

View Article and Find Full Text PDF

Background: Indices of tumor heterogeneity on somatostatin receptor PET/CT scans may potentially serve as predictive biomarkers of treatment efficacy in neuroendocrine tumor (NET) patients undergoing [Lu]Lu-DOTA-TATE PRRT.

Methods: NET patients who underwent [Lu]Lu-DOTA-TATE therapy at the University of Iowa from August 2018 to February 2021 were retrospectively evaluated. Radiomic features on the pre-PRRT somatostatin receptor PET/CT were evaluated using a custom MIM Software® LesionID workflow.

View Article and Find Full Text PDF
Article Synopsis
  • - Phenotypic plasticity in cancer, particularly prostate cancer (PCa), leads to resistance against androgen receptor-targeted therapies, highlighting the need to understand its driving mechanisms to prevent resistance emergence.
  • - The study found that loss of the tristetraprolin (TTP) gene (ZFP36) increases NF-κB activation, correlating with more aggressive disease and recurrence, especially when PTEN, another key driver in PCa, is also lost.
  • - Targeting the NF-κB pathway with an inhibitor (DMAPT) showed promising therapeutic effects in tumors exhibiting co-loss of ZFP36 and PTEN, suggesting a potential new treatment strategy for castration-resistant PCa.
View Article and Find Full Text PDF
Article Synopsis
  • Basophils are rare immune cells that play vital roles in allergic reactions and defense against parasites, but how they activate and produce inflammation is not well understood, prompting research into RNA-binding proteins like tristetraprolin (TTP).
  • Through various experiments, including RNA sequencing and mRNA stability assays on TTP-deficient mice, the study found that without TTP, basophils produce more inflammatory molecules and have prolonged mRNA stability for these mediators.
  • The absence of TTP leads to increased allergic inflammation in a skin model, suggesting that targeting TTP could be a potential therapeutic approach for managing allergies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!